NY-MEDIDATA
29.6.2022 15:02:08 CEST | Business Wire | Press release
Medidata , a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network . AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carnegie Mellon University, University of Rochester, and University of Vermont are now part of the first cross-sector collaboration focused on solving the challenges related to sensor integrations, standardization of sensor data, and the development of novel digital biomarkers and algorithms. These will help to create new digital endpoints that could translate into more effective treatments and better healthcare for patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005239/en/
The Sensor Cloud Network, which includes contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academic institutions, creates opportunities for data scientists to refine, test, and deliver physiological algorithms with clinical meaning at scale. Examples include refined motion parameters like gait, cardiovascular metrics, metabolic insights, and clinical-grade speech analytics.
“As the use of sensors in clinical trials is predicted to reach 50% by 20251 , we are focused on making Medidata Sensor Cloud the industry standard for collecting and analyzing medical-grade sensor data,” said Ben Schlatka, vice president, Digital Biomarker Solutions at Medidata. “We are excited to work with a diverse group of partners to help shape the future of patient data collection and analysis, and make Sensor Cloud the platform of choice for developing new digital biomarkers across a wide variety of therapeutic areas.”
Comments from the newest Sensor Cloud Network partners:
“AliveCor is pleased to join the Medidata Sensor Cloud Network to help facilitate and expand access to clinical trials for a range of serious conditions. Medidata and AliveCor are democratizing clinical research by providing a reliable way to remotely capture and share important heart health data,” said Aman Bhatti, M.D., senior vice president, Global Biopharma, AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology.
"Aural Analytics is thrilled to partner with an industry leader like Medidata. The inclusion of our technology in Medidata’s innovative platform will greatly enhance its capacity for speech collection and analysis," said Judy Smythe, CEO of Aural Analytics, the industry’s leading neuroscience company harnessing the clinical utility of speech across age ranges and around the world.
“We eagerly look forward to collaborating with Medidata and its partners, as we jointly support and advance the decentralized clinical trial (DCT) process with AI-powered remote patient monitoring technology to better aggregate patient data,” said Arik Ben Ishay, CEO of Biobeat , a medtech company with unique health-AI capabilities in the patient monitoring space.
“Blue Spark is excited to become one of the first members of Medidata Sensor Cloud Network. The integration of our TempTraq wearable, wireless continuous temperature monitoring platform gives researchers access to real-time continuous human body temperature data, fed right into the Sensor Cloud Network. TempTraq has been clinically shown to detect fevers up to 18 hours earlier than the standard of care,” said John Gannon, president and CEO of Blue Spark Technologies, Inc., an innovator in wearable, medical device solutions.
“We are very pleased to partner with Medidata’s Sensor Cloud team in making it easier for Life Science organizations to execute global clinical trials, using Glooko’s Connected Research platform. This will benefit researchers in collecting digital endpoints while providing patients with a better trial experience, which will ultimately result in more efficient development of new and novel therapeutics for all disease states,” said Komathi Stem, Chief Operating Officer of Glooko , a digital health company that uses AI/ML algorithms to deliver precision engagement, transform care, and accelerate clinical research.
"We are thrilled to announce this unique partnership with the Medidata Sensor Cloud Network as both of our companies believe that moving clinical research to the home with decentralized data collection will improve the quality of the industry, translating to overall improvements in treatments," said Clint McClellan, CEO, Indie Health , which makes decentralized clinical trials and remote patient monitoring easy, affordable, scalable, and reliable.
“We are leveraging the tools and technology available in the Medidata Sensor Cloud Network to advance and accelerate our work in the development of fall risk detection algorithms in the Multiple Sclerosis population, a disease that affects 2.3M patients worldwide, 50% of whom will experience a fall that negatively impacts their quality of life,” said Dr. Ryan McGinnis, Head of the MSense group at the University of Vermont . “The Sensor Cloud Network is allowing us to explore the combination of patient reported outcomes and medical-grade wearables data in remote settings at scale to better understand this problem and to develop a digital intervention.”
To learn more about the Sensor Cloud Network, please visit here .
Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
- Y. Jansen and G. Thornton, “Wearables & Big Data In Clinical Trials — Where Do We Stand?,” Clinical Leader, February 2020. https://www.clinicalleader.com/doc/wearables-big-data-in-clinical-trials-where-do-we-stand-0001 .
About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata .
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com .
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005239/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 09:00:00 CEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 08:33:00 CEST | Press release
Global study of 276 practitioners across 22 countries defines the “Agentic Gap” and outlines how financial institutions can transition from experimentation to governed, high-impact deployment.Supporting analysis by Oliver Wyman finds reporting absorbs 1% to 3% of total bank expenditure, with a concentrated share of it addressable by agentic workflows. Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embe
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 20281 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements:Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 07:00:00 CEST | Press release
New portfolio combines high-performance cell culture media, molecule-specific CQA optimization, and integrated CDMO capabilities to help biosimilar developers accelerate the path to analytical similarity and improve process economics. OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of
H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications22.9.2026 06:00:00 CEST | Press release
The 700 kW system builds on H2SITE’s previous maritime deployments and is designed as a modular, replicable solution for auxiliary power onboard vessels H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/ Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry. Led by H2SITE, HydraNord
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
